MedPage Today  Jun 26  Comment 
(MedPage Today) -- Exenatide plus dapagliflozin maintained biomarker benefits in long-term study
MedPage Today  Sep 14  Comment 
(MedPage Today) -- Once-weekly exenatide safe for CV outcomes but falls short of showing benefit
MedPage Today  Jun 12  Comment 
(MedPage Today) -- Less need for additional drugs with implantable exenatide versus sitagliptin, placebo
FiercePharma  Oct 13  Comment 
AZ taps 3SBio to help drive sales of diabetes meds Byetta, Bydureon in China phil Thu, 10/13/2016 - 10:00
newratings.com  Sep 16  Comment 
LONDON (dpa-AFX) - AstraZeneca (AZN.L, AZN) announced that the combination Trial of BYDUREON (exenatide extended-release) and FARXIGA (dapagliflozin) has showed significant blood sugar reduction in patients with Type 2 Diabetes. The Phase III...
FiercePharma  Jun 24  Comment 
AstraZeneca, Teva settle Byetta patent suit; generics on their way esagonowsky Fri, 06/24/2016 - 08:58
FierceBiotech  Apr 28  Comment 
Intarcia Therapeutics has raffled off 1.5% of the blockbuster future net revenue it is hoping to see--provided its late-stage, extended-warranty version of exenatide can work as billed with a miniature pump. Unnamed investors have gambled $225...
MedPage Today  Jul 27  Comment 
(MedPage Today) -- The cellular regulatory system known as autophagy appeared to play a key role in preventing type 2 diabetes by protecting insulin-secreting beta cells from the accumulation of toxic amylin oligomers, researchers reported.
StreetInsider.com  Jun 25  Comment 
Visit StreetInsider.com at http://www.streetinsider.com/Corporate+News/Flamel+Technologies+%28FLML%29+Reports+Successful+Preclinical+Testing+of+Exenatide/9611773.html for the full story.


Amylin Pharmaceuticals (NASDAQ: AMLN) is a pharmaceutical company that produces drugs to treat diabetes and obesity. The company currently has two type II diabetes drugs on the market: Simylin and Byetta. The latter is responsible for approximately 90% of the company's sales and is unique in that it promotes moderate weight loss; other diabetes drugs often have the opposite affect. Amylin is poised to take advantage of the rapidly growing market for diabetes and obesity drugs.

There are an estimated 21 million people in the United States with diabetes,[1] and over 30% of the U.S. population is currently eligible for obesity treatment. To augment its chances of success, Amylin has teamed up with pharma giant Eli Lilly and Company (LLY) to market the Byetta domestically and internationally.

Company Overview

Amylin makes its money from the sale of biopharmaceutical products. Currently it has two products on the market: Byetta, a joint diabetes venture with Eli Lilly and Company (LLY), and Symlin, also a diabetes medication. Currently Byetta sales are 10x those of Symlin. This is probably due in part to the fact that Eli Lilly has partnered with AMLN to market the drug both domestically and internationally. That said Amylin is applying for additional patents that would expand the therapeutic uses of Symlin and hopefully increase sales. It is important to note that the company has yet to achieve a profitable year. Because of the long lead time needed to develop drugs and the huge R&D costs, Amylin will need several years of profitable sales to recoup its costs.

Business Financials

In 2009, AMLN earned a total of $758 million in total revenues. This was a decline from its 2008 total revenues of $840 million. However, despite the decrease in revenues, AMLN was able to improve its net income. Between 2008 and 2009, AMLN decreased its net loss from $315 million in 2008 to a net loss of $186 million in 2009.[2]

Key Trends and Forces

Obesity and Diabetes

Amylin's two main products focus on diabetes treatment. A rise in obesity has led to increased cases of diabetes in the U.S.; roughly 30% of the U.S. population is currently eligible for anti-obesity treatment. Roughly 7% of the US population currently has diabetes, and this number is rapidly increasing. The aging US population will likely result in even more cases of diabetes, as the prevalence of diabetes increases among older individuals.[3] Byetta, one of Amylin's two drugs for diabetes, also aids weight loss, an effect most other diabetes medications do not have. Amylin should benefit from the rapidly expanding market for its products.

Research and Development

Amylin is currently developing products in its two therapeutic areas of diabetes and obesity. The first is Exenatide LAR, a medication derived from Byetta and currently in clinical trials. The second, a treatment for obesity, derives from the active ingredients in Symlin. These developmental drugs, however, are not "new" as much as derivatives of current medications. Amylin is looking at other hormonal treatments for obesity, but in general its pipeline is very limited. Unlike larger pharmaceutical companies that may be developing several hundred drugs at a time, Amylin is working on at most five.

Patent Expiration

While Amylin's drugs have only recently hit the market, patent life for pharmaceutical products is very short. After the patent on the drugs expires generic drugs (Biogenerics and Biosimilars) are often introduced. Generic drugs can drive down the price of Amylin's drugs significantly.

International Expansion

Amylin teamed up with Eli Lilly and Company (LLY) in producing Byetta, and the two have successfully sought approval for the medication in the EU. The US population is not the only aging population, and there is a market for diabetes medications in other countries as well. Therefore, this partnership has the potential to make a large impact on AMLN's future earnings.


AMLN is unique relative to its competitors in that it promotes moderate weight loss. Most other drugs either result in very limited weight loss or worse, weight gain. Amylin, also reduces insulin resistance, a major problem caused by type II diabetes. Amylin's primary disadvantage is that its products are injectable whereas many new drugs are taken orally. In general, oral drugs are more palatable for patients. Doctors are also more likely to prescribe an oral therapy like Merck's Januvia because of its greater ease of use. Amylin is also much smaller than its competitors.

  • Novartis AG (NVS): markets Starlix for treatment of type 2 diabetes.
  • AstraZeneca (AZN): currently developing saxagliptin for diabetes.
  • GlaxoSmithKline (GSK): produces Avandia, a huge diabetes medication that recently was linked to cardiovascular risks.
  • Eli Lilly and Company (LLY): sells Actos, an oral diabetes medication in addition to its collaboration with Amylin on Byetta.
  • Merck (MRK): manufactures Januvia, which was launched in 2006 and is a direct competitor to Byetta. Byetta, however, has shown more benefits in weight-loss than Januvia, and it increase insulin levels more effectively than Januvia.


  1. Juvenile Research Foundation International
  2. AMLN 10-K 2009 Item 6 Pg. 43
  3. http://apps.nccd.cdc.gov/ddtstrs/template/ndfs_2005.pdf
Wikinvest © 2006, 2007, 2008, 2009, 2010, 2011, 2012. Use of this site is subject to express Terms of Service, Privacy Policy, and Disclaimer. By continuing past this page, you agree to abide by these terms. Any information provided by Wikinvest, including but not limited to company data, competitors, business analysis, market share, sales revenues and other operating metrics, earnings call analysis, conference call transcripts, industry information, or price targets should not be construed as research, trading tips or recommendations, or investment advice and is provided with no warrants as to its accuracy. Stock market data, including US and International equity symbols, stock quotes, share prices, earnings ratios, and other fundamental data is provided by data partners. Stock market quotes delayed at least 15 minutes for NASDAQ, 20 mins for NYSE and AMEX. Market data by Xignite. See data providers for more details. Company names, products, services and branding cited herein may be trademarks or registered trademarks of their respective owners. The use of trademarks or service marks of another is not a representation that the other is affiliated with, sponsors, is sponsored by, endorses, or is endorsed by Wikinvest.
Powered by MediaWiki